Conatus Pharmaceuticals Inc. (NASDAQ:CNAT)‘s stock had its “buy” rating reaffirmed by investment analysts at JMP Securities in a report released on Wednesday.

Several other equities research analysts also recently issued reports on the company. Zacks Investment Research downgraded Conatus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 19th. Stifel Nicolaus decreased their price target on Conatus Pharmaceuticals from $6.00 to $5.00 and set a “buy” rating for the company in a report on Wednesday. Brean Capital reiterated a “buy” rating and set a $7.00 price target on shares of Conatus Pharmaceuticals in a report on Tuesday, October 4th. Finally, FBR & Co reiterated an “outperform” rating and set a $16.00 price target on shares of Conatus Pharmaceuticals in a report on Tuesday, August 30th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Conatus Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $8.54.

Analyst Recommendations for Conatus Pharmaceuticals (NASDAQ:CNAT)

Shares of Conatus Pharmaceuticals (NASDAQ:CNAT) opened at 1.90 on Wednesday. The firm’s market cap is $37.71 million. The stock’s 50 day moving average price is $1.90 and its 200-day moving average price is $2.08. Conatus Pharmaceuticals has a 12-month low of $1.40 and a 12-month high of $4.05.

Conatus Pharmaceuticals (NASDAQ:CNAT) last issued its earnings results on Tuesday, November 8th. The biotechnology company reported ($0.31) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.03. During the same period last year, the business earned ($0.31) EPS. On average, analysts predict that Conatus Pharmaceuticals will post ($1.34) earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. AXA increased its position in shares of Conatus Pharmaceuticals by 1.4% in the second quarter. AXA now owns 1,085,775 shares of the biotechnology company’s stock worth $2,237,000 after buying an additional 14,939 shares during the period. Vanguard Group Inc. increased its position in shares of Conatus Pharmaceuticals by 3.5% in the second quarter. Vanguard Group Inc. now owns 448,938 shares of the biotechnology company’s stock worth $925,000 after buying an additional 15,300 shares during the period. Bank of New York Mellon Corp increased its position in shares of Conatus Pharmaceuticals by 2.0% in the second quarter. Bank of New York Mellon Corp now owns 86,296 shares of the biotechnology company’s stock worth $178,000 after buying an additional 1,668 shares during the period. Finally, KCG Holdings Inc. acquired a new position in shares of Conatus Pharmaceuticals during the third quarter worth about $135,000. Hedge funds and other institutional investors own 22.89% of the company’s stock.

About Conatus Pharmaceuticals

Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.

5 Day Chart for NASDAQ:CNAT

Receive News & Stock Ratings for Conatus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.